The Prenuvo whole-body MRI screening: (1) can serve as an adjunct to, but is not intended to replace, other established evidence–based screening practices for early detection of specific malignancies (e.g. colonoscopy, dedicated breast imaging, Pap-smear screening for cervical cancer, low-dose chest CT for high risk patients), (2) is effective for visualization of solid lesions on the order of 1 cm or larger within the head, neck, chest, abdomen, and pelvis. As with any medical test, there are limitations, which make it impossible to detect all malignancies and disease conditions, (3) is generally sensitive and specific for detection of cerebral artery aneurysms on the order of 3 mm or greater in size, (4) does not evaluate the heart or heart vessels, (5) does not evaluate lung microarchitecture or pulmonary micronodules, (6) does not replace dedicated breast imaging for screening or diagnostic evaluation (e.g. mammography, breast ultrasound, breast MRI with contrast), (7) is limited in the evaluation of the gastrointestinal tract and does not replace endoscopy or colonoscopy (e.g. cannot detect bowel polyps), (8) is limited in its assessment of the large joints as the exam is not tailored for detailed evaluation of the joint ligaments, cartilage, menisci, and labrum, (9) should not be considered a primary screening modality of the skin. This is best assessed by direct physical examination, (10) is not intended to replace dedicated diagnostic imaging in the setting of specific clinical diagnostic questions.